The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
BACKGROUND: The advent of Remicade® biosimilars, Remsima®, Inflectra® and, more recently, Flixabi®, has brought along the potential to decrease the costs associated with this therapy, therefore increasing its access to a larger group of patients. However, and in order to assure a soft transition, one must make sure the assays and algorithms previously developed and optimized for Remicade perform equally well with its biosimilars. This study aimed to: (a) validate the utilization of Remicade-optimized therapeutic drug monitoring assays for the quantification of Flixabi; and (b) determine the existence of Remicade, Remsima and Flixabi cross-immunogenicity.
METHODS: Healthy donors' sera spiked with Remicade, Remsima and Flixabi were quantified using three different Remicade-quantification assays, and the reactivity of anti-Remicade and anti-Remsima sera to Remicade and to its biosimilars was assessed.
RESULTS: The results show that all tested Remicade-infliximab-optimized assays measure Flixabi as accurately as they measure Remicade and Remsima: the intraclass correlation coefficients between theoretical and measured concentrations varied from 0.920 to 0.990. Moreover, the interassay agreement values for the same compounds were high (intraclass correlation coefficients varied from 0.936 to 0.995). Finally, the anti-Remicade and anti-Remsima sera reacted to the different drugs in a similar fashion.
CONCLUSIONS: The tested assays can be used to monitor Flixabi levels. Moreover, Remicade, Remsima and Flixabi were shown to have a high cross-immunogenicity, which supports their high similarity but prevents their switching in nonresponders with antidrug antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Therapeutic advances in gastroenterology - 11(2018) vom: 01., Seite 1756284818796956 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magro, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biosimilars |
|---|
| Anmerkungen: |
Date Revised 21.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/1756284818796956 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288989236 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288989236 | ||
| 003 | DE-627 | ||
| 005 | 20231225061550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1756284818796956 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0963.xml |
| 035 | |a (DE-627)NLM288989236 | ||
| 035 | |a (NLM)30263065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magro, F |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The advent of Remicade® biosimilars, Remsima®, Inflectra® and, more recently, Flixabi®, has brought along the potential to decrease the costs associated with this therapy, therefore increasing its access to a larger group of patients. However, and in order to assure a soft transition, one must make sure the assays and algorithms previously developed and optimized for Remicade perform equally well with its biosimilars. This study aimed to: (a) validate the utilization of Remicade-optimized therapeutic drug monitoring assays for the quantification of Flixabi; and (b) determine the existence of Remicade, Remsima and Flixabi cross-immunogenicity | ||
| 520 | |a METHODS: Healthy donors' sera spiked with Remicade, Remsima and Flixabi were quantified using three different Remicade-quantification assays, and the reactivity of anti-Remicade and anti-Remsima sera to Remicade and to its biosimilars was assessed | ||
| 520 | |a RESULTS: The results show that all tested Remicade-infliximab-optimized assays measure Flixabi as accurately as they measure Remicade and Remsima: the intraclass correlation coefficients between theoretical and measured concentrations varied from 0.920 to 0.990. Moreover, the interassay agreement values for the same compounds were high (intraclass correlation coefficients varied from 0.936 to 0.995). Finally, the anti-Remicade and anti-Remsima sera reacted to the different drugs in a similar fashion | ||
| 520 | |a CONCLUSIONS: The tested assays can be used to monitor Flixabi levels. Moreover, Remicade, Remsima and Flixabi were shown to have a high cross-immunogenicity, which supports their high similarity but prevents their switching in nonresponders with antidrug antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Flixabi® | |
| 650 | 4 | |a Remicade® | |
| 650 | 4 | |a biosimilars | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 700 | 1 | |a Rocha, C |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira, A I |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, H T |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, I |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, S |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, J |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, C C |e verfasserin |4 aut | |
| 700 | 1 | |a Afonso, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in gastroenterology |d 2008 |g 11(2018) vom: 01., Seite 1756284818796956 |w (DE-627)NLM193041979 |x 1756-283X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2018 |g day:01 |g pages:1756284818796956 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1756284818796956 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2018 |b 01 |h 1756284818796956 | ||